<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198948</url>
  </required_header>
  <id_info>
    <org_study_id>0101-3678/18</org_study_id>
    <nct_id>NCT04198948</nct_id>
  </id_info>
  <brief_title>Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers</brief_title>
  <acronym>INTERGLIKOM</acronym>
  <official_title>Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sarajevo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Hospital Prim. Dr. Abdulah Nakas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sarajevo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proton pump inhibitors (PPIs) are treatment of choice for different gastrointestinal
      disorders common in type 2 diabetes. Sulfonylureas (SUs) are anti-diabetes agents
      particularly widely used in developing countries. Gliclazide, a recommended SU drug, is
      metabolised in part by CYP2C19, the main enzyme responsible for the PPI metabolism.

      A randomised, placebo-controlled, two-sequence, two-period crossover study will be performed
      to explore whether gliclazide pharmacokinetics (PK) and pharmacodynamics (PD) are altered
      upon co-administration with omeprazole. Sixteen healthy volunteers, CYP2C19
      extensive/ultrarapid metabolisers (EM/UM), will receive placebo or omeprazole alone for 4
      days, and concomitantly with single dose of gliclazide on day 5. Plasma concentration of
      gliclazide will be measured for 24 hours, and plasma glucose and insulin levels up to 12
      hours after gliclazide administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gliclazide AUC</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>12 hours</time_frame>
    <description>Change in glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>12 hours</time_frame>
    <description>Change in insulin concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Omeprazole treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.</description>
    <arm_group_label>Omeprazole treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo will be administered orally once daily for 5 days in one of the two treatment periods.</description>
    <arm_group_label>Placebo treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <description>Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.</description>
    <arm_group_label>Omeprazole treatment arm</arm_group_label>
    <arm_group_label>Placebo treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men

          -  Age 18-30 years

          -  Non-smokers

          -  CYP2C19 extensive/ultrarapid metabolisers

        Exclusion Criteria:

          -  medical history of hepatic, renal, gastrointestinal and hematologic disease or any
             acute or chronic disease, or drug allergy to sulfonylureas or PPIs or history of drug
             abuse

          -  abnormalities in physical examination, ECG and routine clinical laboratory tests
             (including fasting blood glucose concentration)

          -  medication use during the 14 days prior and during the study period

          -  grapefruit, grapefruit juice, alcohol, beverages or food containing methylxanthines
             use during 72 h prior and during the study period
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Dujic, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sarajevo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aida Kulo Cesic, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sarajevo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital Prim. Dr. Abdulah Nakas</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
  </location_countries>
  <reference>
    <citation>Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, Qureshi MF, Md Fariduddin, Pathan MF, Jawad F, Bhattarai J, Tandon N, Somasundaram N, Katulanda P, Sahay R, Dhungel S, Bajaj S, Chowdhury S, Ghosh S, Madhu SV, Ahmed T, Bulughapitiya U. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96. doi: 10.4103/2230-8210.163171. Review.</citation>
    <PMID>26425465</PMID>
  </reference>
  <reference>
    <citation>Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014 Jan;30(1):11-22. doi: 10.1002/dmrr.2470. Review.</citation>
    <PMID>24030920</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Si D, Chen X, Lin N, Guo Y, Zhou H, Zhong D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol. 2007 Jul;64(1):67-74. Epub 2007 Feb 12.</citation>
    <PMID>17298483</PMID>
  </reference>
  <reference>
    <citation>Shao H, Ren XM, Liu NF, Chen GM, Li WL, Zhai ZH, Wang DW. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther. 2010 Jun;35(3):351-60. doi: 10.1111/j.1365-2710.2009.01134.x.</citation>
    <PMID>20831536</PMID>
  </reference>
  <reference>
    <citation>Sun XM, Tan JC, Zhu Y, Lin L. Association between diabetes mellitus and gastroesophageal reflux disease: A meta-analysis. World J Gastroenterol. 2015 Mar 14;21(10):3085-92. doi: 10.3748/wjg.v21.i10.3085. Review.</citation>
    <PMID>25780309</PMID>
  </reference>
  <reference>
    <citation>Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010 Sep;70(3):383-92. doi: 10.1111/j.1365-2125.2010.03717.x.</citation>
    <PMID>20716239</PMID>
  </reference>
  <reference>
    <citation>Dujic T, Zhou K, Donnelly LA, Leese G, Palmer CNA, Pearson ER. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. Diabetes Obes Metab. 2018 Jan;20(1):211-214. doi: 10.1111/dom.13046. Epub 2017 Aug 25.</citation>
    <PMID>28656666</PMID>
  </reference>
  <reference>
    <citation>Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0. Review.</citation>
    <PMID>24550106</PMID>
  </reference>
  <reference>
    <citation>Semiz S, Dujic T, Ostanek B, Prnjavorac B, Bego T, Malenica M, Marc J, Causevic A. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J Basic Med Sci. 2010 Nov;10(4):287-91.</citation>
    <PMID>21108610</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sarajevo</investigator_affiliation>
    <investigator_full_name>Tanja Dujic, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

